Clinical Trials Browser

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

NCT00245063 2014-10-02

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2 Completed

25 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00309946 2014-07-31

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Phase 2 Completed

51 enrolled 5 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00243347 2013-10-17

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Phase 1 Completed

19 enrolled 7 charts

Head & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT01262612 2013-07-15

Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion

Phase 2 Terminated

12 enrolled

Thoracic

Pleural Effusion, Malignant

NCT00937482 2013-03-08

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Phase 1 Terminated

18 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Breast Neoplasms, Male

NCT00621361 2012-12-17

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

Phase 1 Completed

62 enrolled

Thoracic

Lung Neoplasms

NCT00539331 2011-06-01

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Phase 1 Terminated

6 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase 1 Completed

40 enrolled

BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell